Format

Send to

Choose Destination
Am J Hematol. 2019 Aug;94(8):E209-E213. doi: 10.1002/ajh.25505. Epub 2019 May 21.

Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.

Chow VA1,2,3, Gopal AK1,2,3, Maloney DG1,2,3, Turtle CJ1,2,3, Smith SD1,2,3, Ujjani CS1,2,3, Shadman M1,2,3, Cassaday RD1,2,4, Till BG1,2,3, Tseng YD2,5, Warren EH1,2,3, Shustov AR1,2,4, Menon MP1,4, Bhark S2,6, Acharya UH1,2,3,7, Mullane E2, Hannan LM1,2,3, Voutsinas JM8, Gooley TA1,8, Lynch RC1,2,3.

Author information

1
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
2
Seattle Cancer Care Alliance, Seattle, Washington.
3
Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington.
4
Department of Medicine, Division of Hematology, University of Washington, Seattle, Washington.
5
Department of Radiation Oncology, University of Washington, Seattle, Washington.
6
Fred Hutchinson Cancer Research Center, Public Health Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
7
Department of Medical Oncology, Divisions of Hematologic Malignancies and Cellular Therapy, Dana Farber Cancer Institute, Boston, Massachusetts.
8
Swedish Cancer Institute, Seattle, Washington.
PMID:
31056762
DOI:
10.1002/ajh.25505

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center